Xencor

Xencor

Xencor

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Founded
1997
Raised
$15M
Follow us
Also headquartered in Monrovia
Alexa global traffic share
Latest funding
$15,000,000
Venture capital (Series E) - 2007
Team Size
50+
Employees
MedCity News

FDA lifts partial hold on Xencor leukemia study

MedCity News

Xencor leukemia trial put on partial hold following two patient deaths